KTTA net incomeQ2 2026-$5.27M
KTTA net income was -$5.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.72M a year earlier. For the full fiscal 2025 it was -$20.43M, compared with -$13.90M in fiscal 2024.
Pasithea Therapeutics Corp. (KTTA) financials
For the twelve months ended Jun 30, 2026, Pasithea Therapeutics Corp. reported -$21.29M of net income.
- Net income, TTM
- -$21.29M
- Cash
- $45.66M
- Market cap
- $19.5M
FY2021FY2022
FY2021FY2025
FY2021FY2023
KTTA revenue and earnings growth
KTTA EPSQ2 2026-$0.16
KTTA diluted EPS was -$0.16 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.91.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $486.6K | $15.1K |
| Cost of revenue | - | - | - | $113.2K | $17.3K |
| Gross profit | - | - | - | $373.4K | -$2.2K |
| Research and development | $7.98M | $7.20M | $8.10M | $2.67M | - |
| Selling, general and admin | $12.88M | $7.05M | $7.88M | $9.92M | $4.51M |
| Operating income | -$20.86M | -$14.25M | -$15.98M | -$12.59M | -$4.51M |
| Interest expense | - | - | - | $102 | $508 |
| Pre-tax income | -$20.43M | -$13.90M | -$15.51M | -$11.73M | -$2.17M |
| Net income | -$20.43M | -$13.90M | -$15.96M | -$13.94M | -$2.17M |
| EPS, basic | -$2.91 | -$12.69 | -$0.42 | -$1.76 | -$0.21 |
| EPS, diluted | -$2.91 | -$12.69 | -$0.42 | -$1.76 | -$0.21 |
| Diluted shares | 7.0M | 1.1M | 1.2M | 1.3M | 10.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $55.16M | $6.92M | $16.33M | $33.09M | $52.90M |
| Current assets | $56.46M | $7.37M | $16.69M | $34.08M | $53.30M |
| Goodwill | - | $1.26M | $1.26M | $1.26M | - |
| Total assets | $60.24M | $16.06M | $26.12M | $45.18M | $53.32M |
| Current liabilities | $4.97M | $1.12M | $2.63M | $1.88M | $447.3K |
| Total liabilities | $5.02M | $1.28M | $2.72M | $2.68M | $1.90M |
| Shareholders' equity | $55.22M | $14.78M | $23.40M | $42.50M | $51.42M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$15.21M | -$13.92M | -$12.81M | -$11.89M | -$3.17M |
| Capital expenditures | - | - | $34.3K | $107.1K | $21.5K |
| Free cash flow | - | - | -$12.85M | -$12.00M | -$3.20M |
| Investing cash flow | $11.0K | - | $75.2K | -$2.30M | -$21.5K |
| Financing cash flow | $63.52M | $4.52M | -$3.73M | -$3.21M | $55.93M |
| Share repurchases | - | - | $3.73M | - | - |
| Stock-based compensation | $297.5K | $773.7K | $592.3K | $835.1K | $471.3K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | 3130.4% | - |
| Gross margin | - | - | - | 76.7% | -14.7% |
| Operating margin | - | - | - | -2587.3% | -29925.7% |
| Net margin | - | - | - | -2864.3% | -14430.5% |
| Free cash flow margin | - | - | - | -2466.6% | -21216.0% |
| Return on equity | -37.0% | -94.1% | -68.2% | -32.8% | -4.2% |
| Return on assets | -33.9% | -86.6% | -61.1% | -30.8% | -4.1% |
| Current ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.69M | $2.94M | $2.74M | $1.36M | $2.15M | $1.73M | $1.51M | $1.58M | $2.36M | $1.75M | $3.35M | $1.62M |
| Selling, general and admin | $2.03M | $1.93M | $7.51M | $1.75M | $1.66M | $1.95M | $1.75M | $1.42M | $1.59M | $2.29M | $1.80M | $2.16M |
| Operating income | -$5.71M | -$4.88M | -$10.26M | -$3.11M | -$3.81M | -$3.68M | -$3.26M | -$3.00M | -$3.95M | -$4.04M | -$5.15M | -$3.79M |
| Pre-tax income | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M | -$3.00M | -$3.87M | -$3.86M | -$5.03M | -$3.61M |
| Net income | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M | -$3.00M | -$3.87M | -$3.86M | -$5.05M | -$3.61M |
| EPS, basic | -$0.16 | -$0.12 | - | -$0.41 | -$0.66 | -$1.61 | -$2.41 | -$2.87 | -$3.71 | -$3.70 | $7.80 | -$2.87 |
| EPS, diluted | -$0.16 | -$0.12 | - | -$0.41 | -$0.66 | -$1.61 | -$2.41 | -$2.87 | -$3.71 | -$3.70 | $7.80 | -$2.87 |
| Diluted shares | 32.1M | 24.3M | - | 7.4M | 5.6M | 2.2M | - | 1.0M | 1.0M | 1.0M | - | 1.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.66M | $50.40M | $55.16M | $4.12M | $7.22M | $5.34M | $6.92M | $9.36M | $7.97M | $12.01M | $16.33M | $19.58M |
| Current assets | $48.24M | $52.73M | $56.46M | $5.53M | $8.64M | $6.12M | $7.37M | $9.78M | $8.64M | $13.19M | $16.69M | $20.77M |
| Goodwill | - | - | - | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M |
| Total assets | $51.71M | $56.35M | $60.24M | $13.63M | $17.01M | $14.66M | $16.06M | $18.64M | $17.66M | $22.41M | $26.12M | $30.66M |
| Current liabilities | $1.84M | $1.49M | $4.97M | $1.38M | $1.74M | $1.59M | $1.12M | $660.4K | $1.39M | $2.47M | $2.63M | $2.04M |
| Total liabilities | $1.87M | $1.54M | $5.02M | $1.42M | $1.83M | $1.68M | $1.28M | $824.0K | $1.49M | $2.52M | $2.72M | $2.28M |
| Shareholders' equity | $49.84M | $54.80M | $55.22M | $12.21M | $15.18M | $12.98M | $14.78M | $17.81M | $16.18M | $19.88M | $23.40M | $28.37M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.71M | -$4.79M | -$5.40M | -$2.89M | -$3.87M | -$3.06M | -$2.44M | -$3.12M | -$4.04M | -$4.32M | -$3.29M | -$3.24M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | -$36 | -$22.7K |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$3.29M | -$3.26M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | $54.5K | $50.2K |
| Financing cash flow | $8.5K | $750 | $56.42M | -$116.1K | $5.74M | $1.47M | -$23.6K | - | - | - | $0 | -$3.86M |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Stock-based compensation | $329.9K | $139.2K | $88.3K | $53.0K | $57.6K | $98.6K | $118.4K | $147.9K | $161.0K | $346.5K | $69.9K | $126.7K |
| Depreciation and amortization | - | - | - | $24.0K | - | - | - | $5.0K | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 26.25 | 35.40 | 11.35 | 4.02 | 4.97 | 3.84 | 6.58 | 14.81 | 6.20 | 5.35 | 6.34 | 10.16 |
Source: XBRL data Pasithea Therapeutics Corp. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KTTA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KTTA | - | - | -$21.29M | - | $19.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
KTTA FAQ
4 questionsIs KTTA profitable?
No. Pasithea Therapeutics Corp. reported a net loss of $21.29M for the twelve months ended Jun 30, 2026.How much cash and debt does KTTA have?
Pasithea Therapeutics Corp. reported $45.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did KTTA last report financial results?
The latest statements here come from Pasithea Therapeutics Corp.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this KTTA financial data come from?
Quantisnow builds these statements from the structured XBRL data Pasithea Therapeutics Corp. files with the SEC. It is provided for information only and is not investment advice.